A medical technology company is to continue its fight against cancer after securing a new investment. Vision RT, a developer of 3D surface imaging systems designed to improve radiotherapy treatments, has received £250,000 from The Capital Fund, a government-backed venture fund aimed at small businesses in London.

A medical technology company is to continue its fight against cancer after securing a new investment. Vision RT, a developer of 3D surface imaging systems designed to improve radiotherapy treatments, has received £250,000 from The Capital Fund, a government-backed venture fund aimed at small businesses in London.

The finance will allow the company to expand its business in the US, where it already has an office in Boston. It will also be used to develop and market its existing products, GateCT and GateRT.

The Capital Fund’s investment director Ian Cameron says the funding will allow the Vision RT team to take the company forward on a more secure footing.

Vision RT was founded in 2001 by chief executive Norman Smith, chief technology officer Ivan Meir and non-executive director Peter Kalms.

Its systems are used in radiotherapy treatment centres such as Massachusetts General Hospital in Boston and London’s Royal Marsden Hospital.